| Source: |
| Type: |
| For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream. In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects. |
| Normal Healthy |
| 5291- | 5-HTP, | Kinetics of l-5-hydroxytryptophan in healthy subjects |
| - | in-vivo, | Nor, | NA |
| 5456- | AF, | Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent |
| - | Trial, | Nor, | NA |
| 5443- | AG, | Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers |
| - | Human, | Nor, | NA |
| 4600- | AgNPs, | Effects of particle size and coating on toxicologic parameters, fecal elimination kinetics and tissue distribution of acutely ingested silver nanoparticles in a mouse model |
| - | in-vivo, | Nor, | NA |
| 5322- | ALC, | Comparison of pharmacokinetics of L-carnitine, Acetyl-L-carnitine and Propionyl-Lcarnitine after single oral administration of L-carnitine in healthy volunteers |
| - | Human, | Nor, | NA |
| 2569- | ART/DHA, | A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction |
| - | Human, | Nor, | NA |
| 5423- | ASTX, | Pharmacokinetic Profile of Astaxanthin Nanoemulsion Using HPLC (High-Performance Liquid Chromatography) With Oral Routes |
| - | in-vivo, | Nor, | NA |
| 5445- | ATV, | Atorvastatin |
| - | NA, | Nor, | NA |
| 5500- | Ba, | Safety, tolerability, and pharmacokinetics of oral baicalein tablets in healthy Chinese subjects: A single‐center, randomized, double‐blind, placebo‐controlled multiple‐ascending‐dose study |
| - | Trial, | Nor, | NA |
| 5654- | BNL, | Pharmacokinetics of natural borneol after oral administration in mice brain and its effect on excitation ratio |
| - | in-vivo, | Nor, | NA |
| 5669- | BNL, | Comparison of pharmacological activity and safety of different stereochemical configurations of borneol: L-borneol, D-borneol, and synthetic borneol |
| - | Review, | Nor, | NA | - | Review, | AD, | NA | - | Review, | Stroke, | NA |
| 5672- | Bor, | A comparative review of the pharmacokinetics of boric acid in rodents and humans |
| - | in-vivo, | Nor, | NA |
| 5879- | CAR, | Pharmacokinetic analysis of thymol, carvacrol and diallyl disulfide after intramammary and topical applications in healthy organic dairy cattle |
| - | in-vivo, | Nor, | NA |
| 6029- | CGA, | Pharmacokinetics of chlorogenic acids absorbed in human plasma and their metabolites following oral ingestion of coffee drink |
| - | Trial, | Nor, | NA |
| 2809- | CUR, | Comparative absorption of curcumin formulations |
| - | in-vivo, | Nor, | NA |
| 2561- | EGCG, | ASA, | Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment |
| - | ex-vivo, | Nor, | NA |
| 2442- | RES, | High absorption but very low bioavailability of oral resveratrol in humans |
| - | in-vitro, | Nor, | NA |
| - | in-vivo, | Nor, | NA |
| 3291- | SIL, | Antioxidant effects and mechanism of silymarin in oxidative stress induced cardiovascular diseases |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:49 Cells:% prod#:% Target#:1109 State#:% Dir#:4
wNotes=0 sortOrder:rid,rpid